The role of pharmacogenetics in cancer therapeutics

doi:10.1111/j.1365-2125.2006.02591.x

Review

. 2006 Jul;62(1):35-46.

doi: 10.1111/j.1365-2125.2006.02591.x.

The role of pharmacogenetics in cancer therapeutics

Wei Peng Yong¹, Federico Innocenti, Mark J Ratain

Affiliations

PMID: 16842377
PMCID: PMC1885075
DOI: 10.1111/j.1365-2125.2006.02591.x

Review

The role of pharmacogenetics in cancer therapeutics

Wei Peng Yong et al. Br J Clin Pharmacol. 2006 Jul.

. 2006 Jul;62(1):35-46.

doi: 10.1111/j.1365-2125.2006.02591.x.

Authors

Wei Peng Yong¹, Federico Innocenti, Mark J Ratain

Affiliation

¹ University of Chicago, Committee on Clinical Pharmacology and Pharmacogenomics, Department of Medicine and Cancer Research Center, Chicago, IL 60637, USA.

PMID: 16842377
PMCID: PMC1885075
DOI: 10.1111/j.1365-2125.2006.02591.x

Abstract

The variability in treatment responses and narrow therapeutic index of anticancer drugs are some of the key challenges oncologists face. The knowledge of pharmacogenetics can potentially aid in the discovery, development and ultimately individualization of anticancer drugs. The identification of genetic variations that predict for drug response is the first step towards the translation of pharmacogenetics into clinical practice. This review provides an update on the results of studies assessing the effects of germline polymorphisms and somatic mutations on therapeutic outcomes and highlights the potential applications and future challenges in pharmacogenetic research pertaining to cancer therapeutics.

PubMed Disclaimer

Cited by

Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series.
Tsai HL, Chen PJ, Chen YC, Li CC, Chang TK, Su WC, Yin TC, Huang CW, Wang JY. Tsai HL, et al. J Int Med Res. 2022 Jul;50(7):3000605221110697. doi: 10.1177/03000605221110697. J Int Med Res. 2022. PMID: 35822291 Free PMC article.
Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer.
Wang Y, Yi C, Wang Y, Li H, Li B, Wang D, Du J, Liu L, Wang X. Wang Y, et al. Oncol Lett. 2017 Nov;14(5):5743-5752. doi: 10.3892/ol.2017.6933. Epub 2017 Sep 14. Oncol Lett. 2017. PMID: 29113203 Free PMC article.
Integrating Epigenomics into Pharmacogenomic Studies.
Zhang W, Huang RS, Dolan ME. Zhang W, et al. Pharmgenomics Pers Med. 2008 Nov;2008(1):7-14. doi: 10.2147/pgpm.s4341. Pharmgenomics Pers Med. 2008. PMID: 20622972 Free PMC article.
Role of pharmacogenomics in drug discovery and development.
Surendiran A, Pradhan SC, Adithan C. Surendiran A, et al. Indian J Pharmacol. 2008 Aug;40(4):137-43. doi: 10.4103/0253-7613.43158. Indian J Pharmacol. 2008. PMID: 20040945 Free PMC article.
Systemic therapies for pancreatic cancer--the role of pharmacogenetics.
Soo RA, Yong WP, Innocenti F. Soo RA, et al. Curr Drug Targets. 2012 Jun;13(6):811-28. doi: 10.2174/138945012800564068. Curr Drug Targets. 2012. PMID: 22458528 Free PMC article. Review.

See all "Cited by" articles

References

1. Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther. 1989;41:535–52. - PubMed
1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329–39. - PubMed
1. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991;119:985–9. - PubMed
1. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19:2293–301. - PubMed
1. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001–8. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database

[1] Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther. 1989;41:535–52. - PubMed

[2] Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther. 1989;41:535–52. - PubMed

[3] Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329–39. - PubMed

[4] Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329–39. - PubMed

[5] Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991;119:985–9. - PubMed

[6] Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991;119:985–9. - PubMed

[7] Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19:2293–301. - PubMed

[8] Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19:2293–301. - PubMed

[9] Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001–8. - PubMed

[10] Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001–8. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The role of pharmacogenetics in cancer therapeutics

Affiliation

The role of pharmacogenetics in cancer therapeutics

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources